MDxHealth (MDXH) Q3 2026 earnings summary

Executive summary

• Q3 results fell short of expectations after accelerated sales-team turnover disrupted commercial execution following the Resolve discontinuation.

• A commercial reorganization split sales and marketing under direct CEO oversight; management expects the team to be fully staffed and trained by Q4-end or entering Q1 2027, with growth returning in 2027.

Financial highlights

• Q3 continuing-operations revenue was $22.711M versus $22.728M a year earlier; 9M revenue rose 9% to $73.817M from $67.685M.

• Q3 operating expenses rose 16% to $22.2M and operating loss widened 86% to $8.128M from $4.4M.

• Continuing-operations net loss rose 26% to $12.259M from $9.7M; adjusted EBITDA was $(6.281)M versus $(0.912)M.

• For 9M, operating loss widened 102% to $21.391M, continuing-operations net loss rose 21% to $31.433M, and adjusted EBITDA was $(13.914)M versus $(0.914)M.

Outlook and guidance

• No Q4 revenue guidance was provided; management expects Q4 revenue broadly in line with Q3, with recovery starting in Q1 2027 and accelerating through the year.

• New sales representatives may need one to two quarters to ramp; management aims to regain prior 20% top-line growth but is unlikely to guide to that rate for 2027.

• Management targets sustainable growth and adjusted EBITDA profitability; it said the prior expectation of positive adjusted EBITDA in Q4 is not as far off as it may seem.

• Strategic AI initiatives are planned for H1 2027, including operational applications and a digital-pathology partnership intended to support GPS.